BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16520665)

  • 1. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
    Bello CL; Sherman L; Zhou J; Verkh L; Smeraglia J; Mount J; Klamerus KJ
    Anticancer Drugs; 2006 Mar; 17(3):353-8. PubMed ID: 16520665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
    Sikes C; Stark JG; McMahen R; Engelking D
    Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    Houk BE; Bello CL; Kang D; Amantea M
    Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.
    Rodamer M; Elsinghorst PW; Kinzig M; Gütschow M; Sörgel F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):695-706. PubMed ID: 21367676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
    Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
    Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
    Szałek E; Karbownik A; Sobańska K; Połom W; Grabowski T; Wolc A; Matuszewski M; Grześkowiak E
    Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2393-9. PubMed ID: 25219843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Food on the Single-dose Pharmacokinetics and Tolerability of Subutinib and its Active Metabolite in Chinese Healthy Volunteers.
    Ding LK; Jia N; Yang L; Li JK; Song W; Wang MH; Wang C; Gao XH; Wen AD
    Drug Res (Stuttg); 2016 Mar; 66(3):160-4. PubMed ID: 26325166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.
    Liew MH; Ng S; Chew CC; Koo TW; Chee YL; Chee EL; Modamio P; Fernández C; Mariño EL; Segarra I
    Invest New Drugs; 2017 Apr; 35(2):145-157. PubMed ID: 28070719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
    Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
    Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
    Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
    Bello CL; Garrett M; Sherman L; Smeraglia J; Ryan B; Toh M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):699-707. PubMed ID: 20049443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Food on the Bioavailability of Omadacycline in Healthy Participants.
    Tzanis E; Manley A; Villano S; Tanaka SK; Bai S; Loh E
    J Clin Pharmacol; 2017 Mar; 57(3):321-327. PubMed ID: 27539539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.
    Vakkalagadda B; Park JS; Ahlers CM; Dorizio S; Has T; Roongta V; Heller KN; Derbin GM; Zhang S
    J Clin Pharmacol; 2012 Sep; 52(9):1350-6. PubMed ID: 22031621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
    Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
    J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
    Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
    Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.